• Company files provisional patent for EdManage Analytics Platform with US patent office
• EdManage carefully aggregates individual parts into new entity that provides insightful, useful and actionable information
• Emaginos believes its EdManage system has potential to make a profound impact on education

Emaginos, a REG-A public company (please see website if interested in investing) in the business of transforming K-12 public education, has filed a patent for its EdManage Analytics Platform (https://ibn.fm/EzYJ5). Emaginos announced earlier this month that it had filed a provisional patent application, titled “Education Analytics Platform,” with the United States Patent and Trademark Office for its proprietary analytics platform designed to aggregate and analyze a school district’s data to deliver actionable information to users throughout the system. “Aristotle is frequently quoted as saying, ‘The whole is greater than the sum of the parts’ — with the clarification that this is only true when the whole emerges as something other than a heap of parts,” said Emaginos president Allan Jones. “If the parts are deliberately combined systematically into some new entity, then through synergy, the new entity emerges. “Calling today’s K-12 public education a ‘system’ is a misnomer,” he continued. “It could better be described as a heap of components trying to collaborate in delivering quality education to the students. The components include everything from student handheld devices to the computer or cloud servers where the applications reside, including the network on which everything communicates. The parts do not magically morph into a smoothly functioning education system. They remain a heap of parts through which educators dig as they try to facilitate learning. For each of the parts, years of usage have evolved them individually to perform their isolated tasks. End of story — until now.” The EdManage analytics platform carefully aggregates these individual parts, morphing them into a new entity that is truly greater — think more insightful, useful and actionable — than the sum of its parts. Emaginos believes its EdManage system has potential to make a profound impact on education. The system integrates all of the devices and applications within a school system that traditionally operate independently, creating cohesive information that can be carefully evaluated. This coming together hasn’t been possible before in the educational space because all the components came from a variety of places and operated independently, using application program interfaces (APIs) and other standards to communicate when needed. EdManage changes this approach, resulting in information that can lead to school district and leaders making important decisions that could transform the way education looks. Emaginos is confident that a well-designed and implemented analytics platform that sheds light on information that previously wasn’t available provides exciting opportunities for those interested in building an educational system that delivers the kind of education that can transform lives. “There is a need to provide and implement such a platform to enhance the ability to efficiently educate children while comprehensively providing an integrated platform to coordinate all operational efforts of increasingly complex school districts,” the company states. EdManage is a key component of the Emaginos Discovery Learning System, enabling constant opportunities to do and understand. The EdManage analytics platform aggregates and analyzes all of a district’s data and then provides previously unattainable actionable information for optimizing every aspect of the district’s operations. For more information about Emaginos and its proprietary analytics platform, as well as to learn about investment and shareholder opportunities, visit www.Emaginos.com NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds
• Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs
• It is one of only a handful of companies moving into Phase 2a clinical trials with a psychedelic compound, and seeks to duplicate the success of GW

As of 2020, the global biotech sector was valued at $753 billion. It is further projected to grow at a compound annual growth rate of 16% between 2021 and 2028 (https://ibn.fm/zidIe). Two key sub-sectors show great promise:  cannabis and psychedelics, which both have significant potential with drug development activities. This value is further evidenced by the recent growth in venture capital investment in these industries and the success of the industry pioneer, GW Pharma, which was acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for $7.2 billion in February 2021 (https://ibn.fm/ia4Du). Between 2019 and 2020, venture capital investment in this sector grew from $100 million to $346 million. So far in 2021, the sector has raised over $329 million. Additionally, Jazz Pharmaceutical’s acquisition of GW Pharma serves as validation of a sector that has tremendous potential for growth while addressing conditions with few existing treatment options (https://ibn.fm/MwYsX). Like GW Pharma’s successful approach with cannabis-derived compounds, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is driving significant innovation with its drug development pipeline using psilocybin-based compounds for the treatment of diseases with high unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program is focused on developing treatments for chronic pain indications including fibromyalgia, phantom limb pain, and complex regional pain syndrome.  The company is also preparing to initiate a Phase 2a clinical trial for eating disorders such as binge eating and hypothalamic obesity. With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds. However, very few have initiated Phase 2a studies. Tryp Therapeutics is one of the few companies that will have initiated multiple Phase 2a clinical studies by the end of 2021. Looking back at GW Pharma and the strides it made, it is easy to see the similarities between the two enterprises, based upon their strategies and the paths taken so far. GW clearly foresaw the huge potential value of drug development for cannabis-derived compounds.  Tryp is pursuing a similar path, but with psychedelic-derived compounds. The investment from GW paid off with the FDA approval of the first-ever cannabis-based drug in June 2018 (https://ibn.fm/36UME). Its premier product, Epidiolex (cannabidiol), designed for controlling seizures in rare forms of epilepsy, generated over $500 million in sales in 2020 alone. Experts project that it could surpass $1 billion soon (https://ibn.fm/K5axF). GW’s FDA drug approval marked a huge milestone, not just for GW Pharma but also for other companies in the evolving biotech space. Tryp is capitalizing on this momentum and the path outlined by GW to create its own success with its PFN program. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• SMEs account for about 60% of China’s production GDP
• However, they have a relatively low adoption of SaaS and automation tools
• Infobird, through innovation and education, is trying to rectify this issue
• By targeting these SMEs, it will be impacting the entire Chinese SaaS market, positioning it as a global leader

As of 2019, the Chinese software-as-a-service SaaS market was estimated between $3.7 billion and $6 billion in value (https://ibn.fm/NBymg). That was just 6% less than the total value of the global SaaS market. This is great for the country. However, when compared to other nations such as the United States, the United Kingdom, Germany, Japan, South Korea, and India, it could use a little more adoption of SaaS and enjoy the benefits and growth that come with it. Infobird (NASDAQ: IFDB) seeks to address that, mainly through innovation and a marketing strategy meant to grow its market share and the SaaS industry in China. Infobird has constantly been pushing the envelope regarding the development and launch of the next generation SaaS in China. By targeting leading industries and specific enterprises within these industries, the company is slowly but surely proving what it can do and its potential for taking over both the Chinese and the global markets (https://ibn.fm/qqhHQ). Currently, small and medium-sized enterprises (“SMEs”) account for about 60% of China’s production GDP. However, their rate of adoption of automation and SaaS is relatively low. This sector’s potential for adopting SaaS far exceeds most markets worldwide, including but not limited to the United States, India, Japan, Germany, and the United Kingdom. Despite its potential, this market is relatively untapped, and Infobird is pushing to fix the situation, firstly educating these organizations and the entrepreneurs therein on the benefits of SaaS, and innovating to suit their needs and wants. Infobird is a SaaS provider focusing on artificial intelligence (“AI”)-powered customer engagement solutions for the Chinese market. Its tech infrastructure is founded on cloud computing, machine learning, patented Voice over Internet Protocol (“VoIP”) application technologies, and AI (https://ibn.fm/EylhH). Since its inception back in October 2001, the company has stayed committed to empowering clients with solutions specifically designed for the issues they face, all while increasing their revenue, reducing costs, enhancing service quality, and overall customer satisfaction. With its focus on SMEs, Infobird is trying to grow China into a leading SaaS market globally. By constantly innovating and tailoring its products and services to the customers, the company is slowly demystifying software and automation in business processes. With its flagship customer engagement software, Infobird can show customers the value of AI customer engagement, along with AI salesforce management. The product, which over 358 customers currently use in industries including health care, education, consumer products, public services, and finance, is proving valuable and essential to improving customer satisfaction and the overall efficiency of an organization’s operations. As such, Infobird is slowly showing its consumers in the Chinese market the value of leveraging its tools and the benefits that come with it. As it currently stands, Infobird’s role is far bigger than the company itself. Through its efforts to innovate and push its products in the market, it is aiding in growing SaaS adoption within China. More importantly, it allows China to grow and achieve its potential to become a global leader in the SaaS market. For more information, visit the company’s website at www.Infobird.com/en/index.html. NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

• Lexaria Bioscience Corp. announced positive results from its VIRAL-A20-2 study
• This study showed strong gains in delivery of the DehydraTECH-enabled remdesivir and ebastine among animals
• The success of this study shows the potential and commercial viability of Lexaria’s DehydraTECH

In June 2021, Lexaria Bioscience (NASDAQ: LEXX) announced positive results from its VIRAL-A20-2 study that evaluated the effectiveness of DehydraTECH-enabled remdesivir and ebastine among animals. The results were strongly positive and demonstrated greater effectiveness than in Lexaria’s first antiviral drug study reported in December 2000. The research was a tolerability and pharmacokinetic (“PK”) study involving four groups of 10 animals each. It examined how they tolerated the DehydraTECH-enhanced drugs, looking for adverse effects as well as improvements in delivery of drugs into bloodstream. It evaluated peak concentration and total drug delivery into the bloodstream. Last month, Lexaria released the results, which showed a three-fold improvement in oral delivery of antiviral drugs (https://ibn.fm/z6Pli). This specific study built on Lexaria’s earlier positive announcement on study VIRAL-C21-3, which showed that both remdesivir and ebastine processed with DehydraTECH effectively inhibited the COVID-19 SARS-CoV-2 virus by using an in vitro screening assay in the infected cells. VIRAL-A20-2 is part of Lexaria’s 2021’s applied research and development (“R&D”) study program that primarily focuses on using DehydraTECH formulations, targeting various application areas, including hypertension, antivirals, NSAIDs, and oral nicotine (https://ibn.fm/La99d). Peak concentration of remdesivir into bloodstream was 110% higher when processed with DehydraTECH than when not processed with Lexaria’s patented technology, and total drug delivery of ebastine into bloodstream was an astonishing 204% higher when processed with DehydraTECH than when not processed “These are the best results Lexaria has ever generated, demonstrating our technology’s ability to more effectively deliver antiviral drugs when taken orally,” noted Chris Bunka, the Chief Executive Officer of Lexaria. “We are starting to see circulating drug levels in the bloodstream that are twice or even three-times higher with DehydraTECH than without, which could greatly enhance opportunities to treat viral infections via oral drug delivery,” he added. On December 1, 2020, Lexaria reported that DehydraTECH processed darunavir posted a 54% improvement in drug delivery into bloodstream over 24 hours with DehydraTECH and efavirenz had a 42% gain in total drug delivery when processed with DehydraTECH. These two antiviral drugs being studied by Lexaria represent two other classes of antiviral therapies under investigation against SARS-CoV-2/COVID-19, currently in use against HIV/AIDS. It marks a significant achievement for the company. Currently, remdesivir is only available in injectable form, given its poor oral bioavailability. As such, this limits its ease and potential breath of commercial use. Ebastine and various other MPro inhibitors also have their share of bioavailability challenges when taken orally. Lexaria, through these R&D studie, seeks to change this to allow for greater drug absorption via capsules instead of traditional injection-only. The VIRAL-A20-2 study focused on peak concentration (“Maximum Concentration” or “Cmax”) as well as the total drug delivery into the rodent bloodstream. The rats were evaluated over the course of 48hrs after dosing to derive the measured Area Under the Curve (“AUClast”) for the entire period. Blood quantitation for remdesivir was conducted by measuring it in its GS-441524 nucleoside analogue metabolite form. It is a prodrug known for its rapid conversion by host cells into its active form following administration. Lexaria Bioscience Corp. is constantly innovating with drug delivery platforms. Its flagship technology, DehydraTECH, is designed to improve how active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods while also increasing the effectiveness of fat-soluble active molecules (https://ibn.fm/ZBA5R). Currently, DehydraTECH is covered by 19 patents issued and over 50 pending patents across 40 different countries in the world. The achievements made so far within the VIRAL-A20-2 study confirms the commercial potential of DehydraTECH to improve drug delivery efficacy. Lexaria expects to be releasing results every month this year from its many ongoing 2021 applied R&D programs. As its validating datasets continue to grow, as proven by its successful VIRAL-A20-2 study, the company seeks to pursue strategic collaboration opportunities with other established pharmaceutical industry partners. The move is geared to allow these partners to utilize and incorporate the DehydraTECH technology with antiviral drugs including those that are currently being studied. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Friendable is currently executing its 120-day strategy, which includes a primary focus on the Fan Pass platform and artist/company revenue
• The global live streaming music market is estimated to reach $24.7 billion by 2027, growing at a CAGR of 9.7%
• Artists on the platform can benefit from the exclusive streaming merchandise opportunities available online, including recording, lighting, and more
• Fan Pass Pro Services are currently up and running, offering options for artist/band logo designs, merch designs, and marketing materials that range in package size – including basic, standard, and premium

Mobile technology and marketing company Friendable (OTC: FDBL) continues to build value in the music streaming industry through the Fan Pass platform, which will mark its one-year anniversary on July 24, 2021. At that time, the company will release a new version of the platform for both desktop and mobile applications, equipped with new features, UI/UX design, and benefits for artists and fans alike. The version 2.0 release is a part of Friendable’s comprehensive 120-day strategy, which also includes:

• A new company/corporate website
• Selling the Friendable dating app – transitioning to 100% focus on the Fan Pass platform
• New technological tools for the artists on the platform
• Paid media rollout for artists, fans, and public Company awareness
• Social media influencer addition
• Uplisting the company
• Rollout of the brand ambassador program
• Adding industry talents, partners, and BOD support
• Building service and subscriber revenue as marketing campaigns scale and diversify
• Rollout of non-fungible tokens (“NFTs”)

The updated version of the Fan Pass platform has been developed based on feedback from the music artists who are members of the platform, to ensure it fully meets their needs and addresses any issues. “The feedback along the way has been both positive and constructive, even overwhelming at times, but it has shown us all along that we have been and continue to be on the right track,” Friendable CEO Robert A. Rositano Jr. said (https://ibn.fm/esV2d). “We are excited to share more, so stay tuned as additional updates will continue to follow as we execute on our plans and the release version 2.0.” Friendable is strategically leveraging its offering to cement its position in the expanding live streaming market, which amounted to $12.8 billion in value worldwide in 2019. The industry is estimated to continue growing at a CAGR of 9.8 percent to reach $24.7 billion by 2027 (https://ibn.fm/Izx1g). The expansion is also driven by a rise in smartphone and smart device popularity, which makes it possible for enhanced online streaming capabilities that Fan Pass platform’s artist members can successfully leverage. Performing artists can use the Fan Pass platform to their advantage by starting their own streaming channel and inviting and engaging with their fans. Artists are then eligible to earn a percentage of the subscriber revenue based on the content views. Additionally, artists can sell tickets to virtual events, earning 100% of the proceeds, while fans get to enjoy concerts on a virtual musical stage from the comfort of their homes or wherever they please. Each month, Friendable offers a contest for artists on the streaming platform. The July Artist Contest is currently underway, offering prizes for first ($500 cash), second ($250 cash), and third ($150) place. The artist with the most merchandise sales in July will also win a custom merch design and collection. The Fan Pass streaming platform is further offering artists the opportunity to upgrade how they stream, with exclusive merchandise, recording equipment, light gear, and more. Some of the items available include GoPro HERO9, USB Microphone, AKAI Professional MPD218, and more. Friendable also provides Fan Pass platform members with fee-based Pro Services to help build their career and brand identity. All Pro Services come in Basic, Standard, and Premium packages and include different tiers of artist/band logo design, merch design, and marketing materials. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• E-commerce and conferencing evolution platform developer Nextech AR Solutions has sealed a contract with a multinational company that has been listed as one of Fortune magazine’s World’s Most Admired Companies over consecutive years
• Nextech also recently announced its acquisition of artificial intelligence innovator Threedy.ai, Inc., which has developed a platform for mass producing 3D images for retailers
• The developments advance Nextech’s opportunities to acquire recurring revenue based on its proprietary LiveX platform
• The global AR market is expected to grow at a CAGR of 43.8 percent by 2028 to $340.16 billion in annual revenues

An agreement announced July 6 between augmented reality (“AR”) digital marketing solutions designer Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) and a multinational company working in the energy and automation space is showcasing Nextech’s ability to deliver large-scale, real-world applications of its platform for brand development and measurable ROI. “The onboarding of another Tier 1 customer is a true testament to our sales team and the solutions we offer global enterprises,” Nextech founder and CEO Evan Gappelberg stated in the news release announcing the contract (https://ibn.fm/dYsTY). “For us, partnerships like this are just the tip of the iceberg. Our menu of offerings allows us to land and then expand into these large organizations who recognize the value of partnering with a seasoned and trusted provider focused on customer success.” Gappelberg noted each new contract provides Nextech with the potential for establishing recurring revenue as the company successfully identifies and fulfills new scopes of work. The multi-year contract with the European-based company listed as one of Fortune magazine’s World’s Most Admired Companies over consecutive years includes an order worth about CA$340,000 to design and deliver a live broadcast, global summit, across several countries later this year, that will use Nextech’s proprietary LiveX platform with technical, multiple-language support, broadcast services, on-demand access, analytics and software licensing, according to the announcement. It follows on the heels of Nextech’s announcement that it has acquired Silicon Valley-based artificial intelligence (“AI”) company Threedy.ai, Inc., which is providing AR shopping solutions at scale for retailers including Kohl’s, Pier1, and K-Mart Australia (https://ibn.fm/aIMTt). Nextech anticipates the acquisition will help it take its AR and 3D marketing solutions to a scalable mass production state. Analysts at Grand View Research, Inc. predict the global AR market will grow to producing revenues of $340.16 billion by 2028 at a CAGR of 43.8 percent between now and then (https://ibn.fm/FbvDM). “People are increasingly adopting the AR-supported online platforms for shopping, education, and social media interactions, among other purposes, for a better immersion experience,” the news release states, adding that innovations in the sector are fueling market growth. The widescale adoption of AR in mobile games and the ubiquitous presence of smartphones and tablets among modern consumers are expected to drive the growth. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• “Forbes” article notes that $20 million Naturo Group acquisition creates ideal situation for BevCanna expansion
• BevCanna boasts one of most unique, diverse portfolios of beverage and natural health products within both cannabis, plant-based industries
• Combination of two Canadian beverage industry leaders unlocks significant potential for growth

As Canadian cannabis company BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) expands its infused functional beverage business into the United States, its deliberate, transformative strategy has garnered a mention in a recent “Forbes” article. Titled “BevCanna Expands in the U.S. Infused Functional Beverage Market Upon Acquiring Naturo Group,” the article noted that the $20 million acquisition created an ideal situation for BevCanna to compete more effectively in the traditional functional beverage category (https://ibn.fm/9deLH). The deal, which was announced late last year, “included a proprietary fulvic and humic plant-based mineral formulation authorized by Health Canada to create a naturally black-colored water under Naturo Group’s signature brand TRACE, as well as its 40,000-square-foot facility,” the article stated, “[making] it the first international company to sell black water in the U.S. alongside domestic band, blk Beverages.” Marcello Leone, who is both the founder of Naturo Group and CEO of BevCanna, noted that the combination of the two Canadian beverage industry leaders unlocks significant potential for growth (https://ibn.fm/piE0T). “The synergies between BevCanna and Naturo are exceptionally strong, and each brings complementary strengths to the table,” Leone said. “BevCanna is a leader in the cannabis-infused beverage and nutraceutical industry while Naturo Group’s innovative plant-based mineral beverage and supplement brand, TRACE, and significant manufacturing infrastructure and international distribution networks, form the foundation of an industry-leading health and wellness company.” With the acquisition completed in February 2021, BevCanna now boasts one of the most unique and diverse portfolios of beverage and natural health products within both the cannabis and plant-based industries. The company is the only fully licensed, in-house and white-label beverage manufacturing company that produces and distributes both conventional and cannabis-based CPG products. The launch of TRACE’s “Original Black Water” will “be our big foray into the U.S. market,” said Leone, who also noted that minerals and other plant-based nutrients in the black water have been known to prevent cognitive degeneration and work together to strengthen the immune system. The launch of TRACE will focus primarily on distributing across independent natural and national retailers. In addition to its alkaline and mineral-infused water expansion into the U.S., the company is focusing on launching its cannabis infused beverages across Canada for white label clients and exclusive partner, Keef Brands, which is currently the number-one infused beverage company in the U.S., said BevCanna president Melise Panetta. The Forbes article observed that BevCanna is taking measures to support TRACE’s launch in the United States, including strengthening its manufacturing capabilities to reduce international shipping and actively fostering relations with local brokers. “Plant-based products account for about 13% of total functional water market right now, but we’re going to see over the next four or five years that they will become a pretty sizable portion of the overall category,” Panetta states. “Products like TRACE seamlessly glide right into that space.” TRACE’s plant-based products are sourced from ancient organic compounds, which are highly concentrated sources of trace minerals. Recognized benefits of the Health Canada-approved formulations include improvements to cognitive performance, gut health and immune function, and stimulating the body to better metabolize carbohydrates, fats and proteins. BevCanna Enterprises is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna management team has decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Ideanomics Chief Scientist and CEO of US Hybrid Dr. Abas Goodarzi recently received the 2021 IEEE PELS Vehicle and Transportation System Achievement Award for his contributions to the advancement of electric powertrains for medium and heavy-duty vehicles
• Dr. Abas is a 38-year veteran in the electric, hybrid, and fuel cell industries
• Prior to his role at Ideanomics, he had worked as an Associate professor at California State University, San Francisco, and later as a Technical Director at General Motors and Senior Scientist at Hughes Aircraft Company

Ideanomics (NASDAQ: IDEX) recently announced that its Chief Scientist and US Hybrid CEO, Dr. Abas Goodarzi, had been named the recipient of this year’s IEEE PELS Vehicle and Transportation Systems Achievement Award. Dr. Abas was recognized at the IEEE Transportation Electrification Conference and Expo (“ITEC”), held virtually between June 21-25, 2021, for his contributions to the advancement of electric powertrains for medium and heavy-duty vehicles (https://ibn.fm/tFVKY). Established in 2019 by the Institution of Electrical and Electronics Engineers (“IEEE”) through its Power Electronics Society (“PELS”), the award is intended to honor and recognize researchers and innovators who have made remarkable technical contributions to the development of power electronics, particularly in the area of vehicle and transportation systems. It is conferred to recipients who satisfy several criteria: advancement of power electronics technology, benefits to the society, sustained impact on the relevant technical community, and the quality of technical achievement and contribution to the field (https://ibn.fm/x3bA6). As an industry veteran with 38 years of experience in the electric, hybrid, and fuel cell industries, Dr. Abas’ contributions and achievements are numerous. The founder of US Hybrid, he previously served as a Technical Director at General Motors (“GM”), where he directed the company’s EV1 powertrain development, and as a Senior Scientist at Hughes Aircraft Company. Prior to his position at GM, he worked as an Associate Professor at California State University, San Francisco. Dr. Abas has co-authored a textbook: Electric Powertrain: Energy Systems, Power Electronics, and Drives for Hybrid, Electric, and Fuel Cell Vehicles. It is this wealth of knowledge that Dr. Abas brings to Ideanomics. “He has done, and continues to do, so much to advance the transition to a zero-emission future in transportation, we are proud to have him as a member of our team to help develop and commercialize industry-changing transportation solutions for now and in the future,” said Ideanomics CEO Alf Poor. The company was pleased to see Dr. Abas’ passion for electric, hybrid, and hydrogen fuel cell development recognized with the well-deserved award. Speaking to Stan Osserman, the host of ThinkTech Hawaii’s YouTube Channel, in a 2019 interview (https://ibn.fm/Wvgzl), Dr. Abas’ fervor and passion for electric vehicles (“EVs”) was immediately evident. When asked about his background and how he ended up running US Hybrid, Dr. Goodarzi noted that his education has always leaned towards EVs. “Everything has been all about making the electric motor more compact, to make it more efficient because, the fuel economy, all of the emission reduction is really due to the electric powertrain,” stated Dr. Abas. At the outset, Dr. Goodarzi’s focus on commercial vehicles was due to their predictable nature. He could easily quantify their emission reduction and fuel savings to clients because they were driven for a prolonged and known period. In contrast, passenger vehicles, which had an unpredictable driving schedule. Indeed, this focus and the accompanying revolutionization within this space have led to the well-deserved IEEE PLS award. Dr. Goodarzi, who was honored to have been recognized, noted that the work has just begun. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers
• With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits
• TumorGenesis will use its GMP lab to produce its proprietary media that tricks tumor cells into growing outside the body the same as inside the body in addition to producing proteins and other biological products used in diagnosing, treating, and modifying tumor cells

On the heels of raising $21.34 million and three of its companies participating in the popular Biotechnology Innovation Organization (“BIO”) conference, Predictive Oncology (NASDAQ: POAI) continued its busy month with more substantive developments from its subsidiaries. The Minneapolis-based company, which develops and offers a suite of products and services across its portfolio companies focused on drug development and targeted cancer treatments, announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new GMP (good manufacturing practices) laboratories (https://ibn.fm/UWoLK). From its facilities in Birmingham, Alabama, Soluble Biotech specializes in formulation solutions and stability services used for vaccines, monoclonal antibodies, and biologics. The GMP facility ramps up these services so the company can rapidly provide clinical-trial-ready formulations to its customers. Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to “significantly increase [the company’s] potential customer base and lead to multiple long-term collaborations.” Interestingly, the lab news arrived less than two weeks after the BIO conference, an event that typically leads to dozens of proposal requests for Soluble Biotech’s services, even before the expanded offerings (https://ibn.fm/To6tz). The lab will also be used to produce the proprietary media used in Soluble Biotech’s chromatography kits. The kits are used by pharmaceutical and biotechnology companies for highly selective removal of endotoxins, toxins inside bacterial cells released upon cell disintegration, as part of the final purification process ahead of clinical or animal studies. Headquartered in the biotech hotbed of Salem, Massachusetts, TumorGenesis will use its new lab to produce media as well, amongst other things. The company’s unique media tricks cancer cells, more specifically cancer and breast cancer cells, into acting in a petri dish (ex-vivo, outside the body) just like they would in vivo (inside the body). In this way, the cells can be tested to help oncologists make better informed decisions on what treatment may improve patient outcomes. The media can also be used in cancer cell editing to produce proteins and other biological products used in diagnosing, treating, and modifying tumor cells. The lab is a synergistic addition to TumorGenesis’ mission to advance leading edge personalized cancer medicine and drug discovery methods. According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that “[TumorGenesis] will be able to meet the needs of researchers who are exploring ways to use the cancer cell’s own mechanisms to produce a target, expressed protein or biological target.” Going forward, investors will be on the lookout for developments in the construction, qualifications and commissioning of the new labs as significant value adds to both subsidiaries and the parent company. From there, the interest will fall into how the GMP facilities translate to additional revenue and profits. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Emaginos is projecting more than $6.5 million in first year of operation; that number is projected to reach almost $27 billion a decade later based on company assumptions
• Gallup poll reports barely half of those surveyed were satisfied with the overall quality of education
• Market demand is high for a scalable solution that will produce profoundly better results for existing funds invested

Emaginos is a REG-A public company (please see website if interested in investing) in the business of transforming K-12 public education. A well-known adage states that actions speak louder than words, and in the case of Emaginos, whose business model is projected to capture up to 40% of the total K-12 education market within the next decade based on company assumptions, the volume of the company’s actions is high. Take a look at the projected financials Emaginos is sharing as it prepares to enter change the education landscape (https://ibn.fm/zsaFv). Currently, the company reports there are 130,930 K-12 public schools with an estimated 50.8 million children enrolled and 3.2 million teachers employed. Public-school expenditures total around $612.7 billion. That’s a lot of students, teachers and money — all working together in efforts that are often disappointing. In fact, the Gallup poll’s annual poll regarding Americans’ satisfaction with U.S. education in 2019 — the last year not impacted by COVID-19 — just 51% of those surveyed were satisfied with the overall quality of education that students in kindergarten through grade 12 receive (https://ibn.fm/g924J); Gallup noted that, since 2005, that number averages 45%, with less than half of those polled happy with public education. Clearly there is room for improvement. “Market demand is high for a scalable solution that will produce profoundly better results for existing funds invested,” the company states. “The United States government has identified effective education as one of the critical elements in address the current financial and unemployment crisis.” Detailed growth projections for Emaginos’ share of the market start with the company implementing its proprietary Discovery Learning System in only 10 schools — pilot schools located in 10 different school districts. An estimated 5,110 students and teachers will be involved, and the company is projected to see $6,522, 218 in annual gross revenue. As districts experience the powerful changes that the Emaginos system delivers, those numbers are estimated to increase dramatically. In only 10 years, the company believes it will be operating in 9,000 schools, with more than 21,000,000 teachers and students involved, resulting in almost $27 billion gross revenue, or between 35% to 40% of the total K-12 education market. The first company with an actionable plan to transform and improve public schools rather than replace them, Emaginos will evoke this change without any additional funding, facilities or staff. In fact, in many cases, school districts may actually save money as they subscribe to and implement the Emaginos platform. For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos